首页> 外文期刊>Vox Sanguinis: International Journal of Blood Transfusion and Immunohaematology >Molecular basis of the rare gene complex, DIVa(C)-, which encodes four low-prevalence antigens in the Rh blood group system
【24h】

Molecular basis of the rare gene complex, DIVa(C)-, which encodes four low-prevalence antigens in the Rh blood group system

机译:稀有基因复合物DIVa(C)-的分子基础,该复合体在Rh血型系统中编码四种低流行性抗原

获取原文
获取原文并翻译 | 示例
       

摘要

Background Over 40years ago, an unusual Rh phenotype denoted DIVa(C)- was identified in a case of fatal haemolytic disease of the newborn in the third child of Madame Nou. Her RBCs expressed a partial D, weak C and four low-prevalence Rh antigens: Go a (RH30), Rh33 (RH33), Riv (RH45) and FPTT (RH50). The purpose of this study was to determine the molecular basis associated with this rare DIVa(C)- complex. Material and Methods Blood samples were from three donors previously identified as carrying the DIVa(C)- haplotype. Molecular analyses were performed by standard methods. Results The three donors were heterozygous for RHD and RHD*DIVa.2, and all carried a compound hybrid allele at the RHCE locus. This hybrid RHCE allele contained exons 2 and 3 from RHD*DIVa.2 and exon 5 from RHD [RHCE*CE-DIVa.2(2-3)-CE-D(5)-CE] and is in cis to RHD*DIVa.2. The RHCE allele on the in trans chromosome differs between the donors and is RHCE*cE in donor 1, RHCE*ce (254C, 733G) in donor 2 and RHCE*ce in donor 3. Conclusions The RHD*DIVa.2 encodes the Go a antigen, whereas the compound hybrid allele most likely encodes Rh33, Riv and FPTT. The weakly expressed C antigen on RBCs with the DIVa(C)- phenotype could be encoded by exons 2 and 3 from RHD*DIVa.2 in the compound hybrid. This is the first report of RHD*DIVa.2 being involved in a hybrid gene at the RHCE locus. As only one example of anti-Riv has been described, our molecular analysis and findings provide a tool by which to predict Riv expression.
机译:背景超过40年前,在Noo夫人的第三个孩子的新生儿中发生致命的溶血性​​疾病的病例中,发现了一个不常见的Rh表型,称为DIVa(C)-。她的RBC表达部分D,弱C和四种低流行Rh抗原:Go a(RH30),Rh33(RH33),Riv(RH45)和FPTT(RH50)。这项研究的目的是确定与此稀有DIVa(C)-复合物相关的分子基础。材料和方法血液样本来自先前确定为携带DIVa(C)-单倍型的三位供体。分子分析通过标准方法进行。结果3个供体在RHD和RHD * DIVa.2上是杂合的,并且都在RHCE位点携带了一个复合杂种等位基因。该杂种RHCE等位基因包含RHD * DIVa.2的外显子2和3和RHD [RHCE * CE-DIVa.2(2-3)-CE-D(5)-CE]的外显子5,与RHD *呈顺式DIVa.2。反式染色体上的RHCE等位基因在供体之间是不同的,在供体1中为RHCE * cE,在供体2中为RHCE * ce(254C,733G),在供体3中为RHCE * ce。结论RHD * DIVa.2编码Go杂合等位基因最有可能编码Rh33,Riv和FPTT。具有DIVa(C)-表型的RBC上表达较弱的C抗原可以由复合杂合体中RHD * DIVa.2的外显子2和3编码。这是RHD * DIVa.2在RHCE位点参与杂种基因的首次报道。正如仅描述了一个抗Riv的例子,我们的分子分析和发现提供了一种预测Riv表达的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号